{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:44:52Z","timestamp":1792025092949,"version":"4.4.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pemivibart received emergency use authorization for COVID-19 prevention in certain individuals with immunocompromise based on immunobridging calculated serum virus-neutralizing antibody (csVNA) titers. We report an analysis of measured (msVNA) titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants before and after receipt of pemivibart in a SARS-CoV-2 immune-experienced population (CANOPY) and compare the relationship between csVNA and msVNA titers in 2 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The trials were conducted during 2023\u20132024. In the phase 3 CANOPY trial, participants with (cohort A) or without (cohort B) significant immunocompromise received 2 intravenous 4500-mg pemivibart or placebo infusions 90 days apart. In the phase 1 trial, healthy adults received a single intravenous dose of pemivibart (1500, 2500, or 4500 mg). msVNA titers were determined using a SARS-CoV-2 spike pseudotyped assay; csVNA titers were calculated as serum pemivibart concentrations divided by variant-specific IC50 values from in vitro neutralization assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In CANOPY, predose msVNA geometric mean titers (GMTs) to the dominant circulating XBB.1.5 lineage were low across cohorts (range, 78.6\u2013119.8), suggesting inadequate protection. msVNA titers were substantially higher against earlier Delta (B.1.617.2) and BA.4\/5 variants. Pemivibart increased the day-28 msVNA GMT &amp;gt;55-fold against XBB.1.5, with similar levels in both cohorts. Across trials, csVNA titers were significantly correlated with msVNA titers (all Spearman correlation coefficients \u22650.73, P &amp;lt; .0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data show that previous immune experience to earlier pandemic variants provided limited cross-protection and demonstrate that pemivibart increased protective titers against newly circulating SARS-CoV-2 in individuals with and without immunocompromise. Notably, csVNA titers effectively predicted pemivibart's neutralization potential.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT06039449 and NCT05791318.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag269","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:44:39Z","timestamp":1779277479000},"page":"e859-e868","source":"Crossref","is-referenced-by-count":1,"title":["Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-4783","authenticated-orcid":false,"given":"Kristin","family":"Narayan","sequence":"first","affiliation":[{"name":"Invivyd, Inc. , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazima","family":"Tosh","sequence":"additional","affiliation":[{"name":"Invivyd, Inc. , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Holmes","sequence":"additional","affiliation":[{"name":"Invivyd, Inc. , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leijun","family":"Hu","sequence":"additional","affiliation":[{"name":"LH Pharmaceutical Consulting, LLC , Carmel, Indiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep Reddy","family":"Dkottam","sequence":"additional","affiliation":[{"name":"Invivyd, Inc. , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilker","family":"Yalcin","sequence":"additional","affiliation":[{"name":"Invivyd, Inc. , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wingertzahn","sequence":"additional","affiliation":[{"name":"Invivyd, Inc. , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026101419582471600_jiag269-B1","author":"Centers for Disease Control and Prevention"},{"key":"2026101419582471600_jiag269-B2","author":"Centers for Disease Control and Prevention"},{"key":"2026101419582471600_jiag269-B3","doi-asserted-by":"crossref","first-page":"e2350145","DOI":"10.1001\/jamanetworkopen.2023.50145","article-title":"Inpatient costs of treating patients with COVID-19","volume":"7","author":"Kapinos","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026101419582471600_jiag269-B4","author":"World Health Organization"},{"key":"2026101419582471600_jiag269-B5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/03007995.2023.2233819","article-title":"Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study","volume":"39","author":"Ketkar","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"2026101419582471600_jiag269-B6","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1093\/cid\/ciaa1012","article-title":"Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)","volume":"72","author":"Kim","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026101419582471600_jiag269-B7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 - COVID-NET, 10 states, March 2020-February 2022","volume":"71","author":"Singson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026101419582471600_jiag269-B8","doi-asserted-by":"crossref","first-page":"869","DOI":"10.15585\/mmwr.mm7339a2","article-title":"COVID-19-associated hospitalizations among U.S. Adults aged \u226518 years - COVID-NET, 12 states, October 2023-April 2024","volume":"73","author":"Taylor","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026101419582471600_jiag269-B9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s40635-025-00831-y","article-title":"Impaired serum neutralization and death in Omicron-infected critically ill patients: insights from the French SEVARVIR prospective, multicenter cohort study","volume":"13","author":"Bruel","year":"2025","journal-title":"Intensive Care Med Exp"},{"key":"2026101419582471600_jiag269-B10","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/s41467-023-39292-w","article-title":"Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration","volume":"14","author":"Follmann","year":"2023","journal-title":"Nat Commun"},{"key":"2026101419582471600_jiag269-B11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"2026101419582471600_jiag269-B12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3201\/eid2902.221422","article-title":"Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection","volume":"29","author":"Khoury","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2026101419582471600_jiag269-B13","doi-asserted-by":"crossref","first-page":"eadg2783","DOI":"10.1126\/scitranslmed.adg2783","article-title":"Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers","volume":"15","author":"Schmidt","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026101419582471600_jiag269-B14","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-023-40204-1","article-title":"Monoclonal antibody levels and protection from COVID-19","volume":"14","author":"Stadler","year":"2023","journal-title":"Nat Commun"},{"key":"2026101419582471600_jiag269-B15","doi-asserted-by":"crossref","first-page":"e202451606","DOI":"10.1002\/eji.202451606","article-title":"Passive immunization in the prevention and treatment of viral infections","volume":"55","author":"Moirangthem","year":"2025","journal-title":"Eur J Immunol"},{"key":"2026101419582471600_jiag269-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-042420-113838","article-title":"SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment","volume":"73","author":"Li","year":"2022","journal-title":"Annu Rev Med"},{"key":"2026101419582471600_jiag269-B17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/cid\/ciaf265","article-title":"Safety and efficacy of pemivibart, a long-acting monoclonal antibody, for prevention of symptomatic COVID-19: interim results from the CANOPY clinical trial","volume":"81","author":"Wolfe","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026101419582471600_jiag269-B18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(24)00804-1","article-title":"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial","volume":"25","author":"Haidar","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026101419582471600_jiag269-B19","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"2026101419582471600_jiag269-B20"},{"key":"2026101419582471600_jiag269-B21","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMc2404555","article-title":"Immunobridging for pemivibart, a monoclonal antibody for prevention of COVID-19","volume":"391","author":"Schmidt","year":"2024","journal-title":"N Engl J Med"},{"key":"2026101419582471600_jiag269-B22","author":"Yalcin"},{"key":"2026101419582471600_jiag269-B23","doi-asserted-by":"crossref","first-page":"e1517","DOI":"10.1002\/cti2.1517","article-title":"Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitroIC(50) values predict SARS-CoV-2 neutralising antibody titres","volume":"13","author":"Clegg","year":"2024","journal-title":"Clin Transl Immunology"},{"key":"2026101419582471600_jiag269-B24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40121-023-00794-1","article-title":"Safety, pharmacokinetics, serum neutralizing titers, and immunogenicity of adintrevimab, a monoclonal antibody targeting SARS-CoV-2: a randomized, double-blind, placebo-controlled, phase 1 dose-escalation study in healthy adults","volume":"12","author":"Schmidt","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026101419582471600_jiag269-B25","doi-asserted-by":"crossref","first-page":"23921","DOI":"10.1038\/s41598-021-03154-6","article-title":"Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"2026101419582471600_jiag269-B26"},{"key":"2026101419582471600_jiag269-B27","author":"Holmes"},{"key":"2026101419582471600_jiag269-B28","doi-asserted-by":"crossref","first-page":"ofad500.1200","DOI":"10.1093\/ofid\/ofad500.1200","article-title":"1363. preliminary safety results from a phase 1 first in human study of VYD222: an extended half-life monoclonal antibody (mAb) in development for COVID-19 prevention","volume":"10","author":"Mahoney","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026101419582471600_jiag269-B29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fpsyg.2017.00456","article-title":"Repeated measures correlation","volume":"8","author":"Bakdash","year":"2017","journal-title":"Front Psychol"},{"key":"2026101419582471600_jiag269-B30","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"},{"key":"2026101419582471600_jiag269-B31","author":"Invivyd"},{"key":"2026101419582471600_jiag269-B32","author":"Invivyd"},{"key":"2026101419582471600_jiag269-B33","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1093\/infdis\/jiae067","article-title":"Interim report of the reactogenicity and immunogenicity of severe acute respiratory syndrome Coronavirus 2 XBB-containing vaccines","volume":"230","author":"Chalkias","year":"2024","journal-title":"J Infect Dis"},{"key":"2026101419582471600_jiag269-B34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.immuni.2024.02.017","article-title":"Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants","volume":"57","author":"Johnston","year":"2024","journal-title":"Immunity"},{"key":"2026101419582471600_jiag269-B35","doi-asserted-by":"crossref","first-page":"e162192","DOI":"10.1172\/JCI162192","article-title":"Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity","volume":"133","author":"Aguilar-Bretones","year":"2023","journal-title":"J Clin Invest"},{"key":"2026101419582471600_jiag269-B36","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1038\/s41467-024-47451-w","article-title":"Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin","volume":"15","author":"Pusnik","year":"2024","journal-title":"Nat Commun"},{"key":"2026101419582471600_jiag269-B37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","article-title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"key":"2026101419582471600_jiag269-B38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15585\/mmwr.mm7406a1","article-title":"Interim estimates of 2024\u20132025 COVID-19 vaccine effectiveness among adults aged \u226518 years - VISION and IVY networks, September 2024-January 2025","volume":"74","author":"Link-Gelles","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag269\/68352481\/jiag269.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/4\/e859\/68352481\/jiag269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/4\/e859\/68352481\/jiag269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:58:29Z","timestamp":1792022309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/4\/e859\/8688849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag269","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,5,21]]}}}